A detailed history of Rock Springs Capital Management LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 4,684,476 shares of TVTX stock, worth $80.5 Million. This represents 2.23% of its overall portfolio holdings.

Number of Shares
4,684,476
Previous 4,482,265 4.51%
Holding current value
$80.5 Million
Previous $36.8 Million 77.87%
% of portfolio
2.23%
Previous 1.14%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.89 - $15.21 $1.6 Million - $3.08 Million
202,211 Added 4.51%
4,684,476 $65.5 Million
Q2 2024

Aug 14, 2024

BUY
$5.26 - $8.28 $5.56 Million - $8.76 Million
1,057,447 Added 30.88%
4,482,265 $36.8 Million
Q1 2024

May 15, 2024

BUY
$7.18 - $9.82 $4.69 Million - $6.42 Million
653,372 Added 23.58%
3,424,818 $26.4 Million
Q4 2023

Feb 14, 2024

BUY
$5.44 - $9.5 $5.24 Million - $9.16 Million
963,704 Added 53.31%
2,771,446 $24.9 Million
Q3 2023

Nov 14, 2023

BUY
$7.64 - $17.25 $2.14 Million - $4.83 Million
280,022 Added 18.33%
1,807,742 $16.2 Million
Q2 2023

Aug 14, 2023

BUY
$15.3 - $22.61 $3.84 Million - $5.68 Million
251,070 Added 19.67%
1,527,720 $23.5 Million
Q1 2023

May 15, 2023

BUY
$17.82 - $22.89 $5.79 Million - $7.44 Million
325,000 Added 34.15%
1,276,650 $28.7 Million
Q4 2021

Feb 14, 2022

SELL
$24.34 - $31.17 $13.3 Million - $17 Million
-545,167 Reduced 36.42%
951,650 $29.5 Million
Q3 2021

Nov 15, 2021

BUY
$12.98 - $25.03 $34,435 - $66,404
2,653 Added 0.18%
1,496,817 $36.3 Million
Q2 2021

Aug 16, 2021

BUY
$14.11 - $26.4 $262,446 - $491,040
18,600 Added 1.26%
1,494,164 $21.8 Million
Q1 2021

May 17, 2021

BUY
$23.37 - $31.77 $10.6 Million - $14.4 Million
454,564 Added 44.52%
1,475,564 $36.8 Million
Q4 2020

Feb 16, 2021

BUY
$19.17 - $27.87 $19.6 Million - $28.5 Million
1,021,000 New
1,021,000 $27.8 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.1B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.